Identification | Back Directory | [Name]
Benzenamine, N-(4-chlorophenyl)-3-(1H-pyrazol-4-yl)- | [CAS]
2444764-03-6 | [Synonyms]
Benzenamine, N-(4-chlorophenyl)-3-(1H-pyrazol-4-yl)- | [Molecular Formula]
C15H12ClN3 | [MDL Number]
MFCD31813592 | [MOL File]
2444764-03-6.mol | [Molecular Weight]
269.73 |
Chemical Properties | Back Directory | [Boiling point ]
504.5±45.0 °C(Predicted) | [density ]
1.320±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 200 mg/mL (741.48 mM) | [form ]
Solid | [pka]
13.93±0.50(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
GKI-1 is a Greatwall (GWL) kinase inhibitor with IC50s of 4.9 and 2.5 μM against hGWLFL and hGWL-KinDom, respectively. GKI-1 robustly inhibits ROCK1 with an IC50 of 11 μM, but only weakly affected PKA[1]. | [storage]
Store at -20°C | [References]
[1] Ocasio CA, et al. A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct. Oncotarget. 2016 Nov 1;7(44):71182-71197. DOI:10.18632/oncotarget.11511 |
|
Company Name: |
Biorbyt Ltd.
|
Tel: |
+44 (0)1223 859 353 |
Website: |
http://www.biorbyt.com |
Company Name: |
MedChemExpress
|
Tel: |
021-58955995 |
Website: |
www.medchemexpress.com |
|